source
- BioMarin's BMN-401 fails key endpoint in ENPP1 deficiency Phase 3 trialAn experimental therapy, BMN 401, was tested in a Phase 3 study for ENPP1 deficiency, a rare disease. The drug missed one of its two co-primary endpoints, a result that regulators consider critical…
- Novo Nordisk streamlines R&D to speed discovery, adds AI to integrated research teamsNovo Nordisk's new CEO Maziar Mike Doustdar, who took the helm in the summer of 2025, announced a reorganization of the company's R&D structure. Jacob Sten Petersen, head of global research, expla…